Chembio Diagnostics, Inc. (CEMI)

NASDAQ: CEMI · IEX Real-Time Price · USD
0.812
-0.034 (-4.01%)
At close: Aug 17, 2022 4:00 PM
0.870
+0.058 (7.169%)
After-hours: Aug 17, 2022 5:44 PM EDT
-4.01%
Market Cap 24.54M
Revenue (ttm) 60.61M
Net Income (ttm) -36.08M
Shares Out 30.22M
EPS (ttm) -1.43
PE Ratio n/a
Forward PE 6.72
Dividend n/a
Ex-Dividend Date n/a
Volume 3,172,836
Open 0.830
Previous Close 0.846
Day's Range 0.753 - 0.867
52-Week Range 0.420 - 3.380
Beta 1.65
Analysts Sell
Price Target 8.16 (+905.2%)
Earnings Date Aug 4, 2022

About CEMI

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly th... [Read more...]

Industry Health Care Equipment & Supplies
IPO Date Oct 18, 2000
Employees 337
Stock Exchange NASDAQ
Ticker Symbol CEMI
Full Company Profile

Financial Performance

In 2021, CEMI's revenue was $47.82 million, an increase of 47.27% compared to the previous year's $32.47 million. Losses were -$33.90 million, 32.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for CEMI stock is "Sell." The 12-month stock price forecast is 8.16, which is an increase of 905.17% from the latest price.

Price Target
$8.16
(905.17% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Chembio Diagnostics Evaluates Monkeypox Rapid Point-of-Care Test Development

HAUPPAUGE, N.Y., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced it is e...

Chembio Diagnostics to Report Second Quarter 2022 Financial Results on August 4, 2022

HAUPPAUGE, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will rele...

Chembio Diagnostics Announces Expansion of Direct-to-Consumer Commercial Channel

Initiates distribution of SCoV-2 Ag Detect Self-Test to consumers in the United States and expansion of SURE CHECK HIV Self-Test distribution to consumers in Brazil and the United Kingdom Initiates dist...

Chembio Diagnostics Announces Election of Leslie Teso-Lichtman to Its Board of Directors

HAUPPAUGE, N.Y., May 24, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the elect...

Chembio Diagnostics Announces Agreement for Reszon Diagnostics International to Manufacture Chembio's HIV 1/2 STAT-PA...

HAUPPAUGE, N.Y., May 17, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has en...

Chembio Diagnostics Reports First Quarter 2022 Financial Results

HAUPPAUGE, N.Y., May 05, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today...

Chembio Diagnostics to Report First Quarter 2022 Financial Results on May 5, 2022

HAUPPAUGE, N.Y., April 21, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will rel...

Despite More Than Double Q4 Sales, Chembio Diagnostics Posts Deeper Losses

Chembio Diagnostics Inc's (NASDAQ: CEMI) Q4 sales increased 101% Y/Y to $20.6 million, beating the consensus of $13.55 million. Net product sales increased 154% to $17.4 million.

Why Chembio Diagnostics Shares Are Falling

Chembio Diagnostics Inc (NASDAQ: CEMI) shares are trading lower by 12.4% at $0.81 after the company reported worse-than-expected fourth-quarter adjusted EPS results. Chembio Diagnostics reported quarter...

Chembio Diagnostics Reports Fourth Quarter and Full Year 2021 Financial Results

HAUPPAUGE, N.Y., March 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, tod...

Chembio Diagnostics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

HAUPPAUGE, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today reported that, in accordance...

Chembio Diagnostics Announces Appointment of Larry Steenvoorden as Chief Financial Officer

HAUPPAUGE, N.Y., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the appointment o...

FDA Asks Chembio Additional Data On HIV-Syphilis Test For CLIA Waiver

Chembio Diagnostics Inc's (NASDAQ: CEMI) said that on December 1, it received an FDA notice for additional data related to Clinical Laboratory Improvement Amendment (CLIA) waiver submission for the DPP ...

Chembio Diagnostics Submits FDA De Novo/510(k) Request for DPP SARS-CoV-2 Antigen Test System

HAUPPAUGE, N.Y., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it has submi...

Chembio Diagnostics' DPP COVID-19 Antigen Test Approved In South Africa

South Africa Health Products Regulatory Authority (SAHPRA) has approved Chembio Diagnostics Inc's (NASDAQ:CEMI) DPP SARS-CoV-2 Antigen test for use at the point of care. The DPP SARS-CoV-2 Antigen test ...

Chembio Files For FDA Emergency Use Nod For COVID-19 Antigen Test

Chembio Diagnostics Inc (NASDAQ:CEMI) submitted an Emergency Use Authorization (EUA) application to the FDA for the new DPP SARS-CoV-2 Antigen test. The DPP SARS-CoV-2 Antigen test system has been desig...

Chembio Diagnostics Submits EUA Application for New DPP SARS-CoV-2 Antigen Test

HAUPPAUGE, N.Y., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission of...

Chembio Diagnostics to Report Third Quarter 2021 Financial Results on November 4, 2021

HAUPPAUGE, N.Y., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will rele...

Chembio Announces EUA Submission for DPP Respiratory Antigen Panel

Test Provides Simultaneous Detection of Flu A, Flu B, and SARS-CoV-2 Test Provides Simultaneous Detection of Flu A, Flu B, and SARS-CoV-2

Why Chembio Diagnostics Shares Are Trading Higher Today

Chembio Diagnostics Inc (NASDAQ: CEMI) is trading higher Friday after the company announced its launch of commercial distribution of SCOV-2 Ag Detect Rapid Test, a third party COVID-19 antigen assay. Ch...

Chembio Starts Distribution of Third-Party COVID-19 Antigen Assay

Chembio Diagnostics Inc (NASDAQ: CEMI) has launched the commercial distribution of an FDA-Emergency Use Authorized rapid point-of-care COVID-19 antigen test.  Product inventory is on-hand and immediatel...

Chembio Launches Commercial Distribution of Third-Party COVID-19 Antigen Assay

HAUPPAUGE, N.Y., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced its launch of com...

Implied Volatility Surging for Chembio Diagnostics (CEMI) Stock Options

Investors need to pay close attention to Chembio Diagnostics (CEMI) stock based on the movements in the options market lately.

Chembio Diagnostics Stock Falls As Q2 Earnings Lag Consensus, Doubt On Ability To Continue As Going Concern

Chembio Diagnostics Inc's (NASDAQ: CEMI) Q2 sales increased 26% Y/Y to $6.5 million, missing the consensus of $8.5 million. Net product sales increased 4% to $3.9 million.

Find Cheap Stocks Under $10 to Buy in August

August appears to be a solid time to consider adding stocks. Today we looked at how to screen for highly-ranked stocks trading for under $10 a share.

Other symbols: LXSIRI